ONIVYDE® (irinotecan liposome injection) is indicated, in combination with fluorouracil (5-FU) and leucovorin (LV), for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.
Limitation of Use: ONIVYDE is not indicated as a single agent for the treatment of patients with metastatic adenocarcinoma of the pancreas.
Please see full Prescribing Information, including Boxed WARNINGS.
References: 1. ONIVYDE® [package insert]. Basking Ridge, NJ. Ipsen Biopharmaceuticals, Inc.; 2017. 2. Wang-Gillam A, Li C-P, Bodoky G, et al. Lancet. 2016;387:545-557. 3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Pancreatic Adenocarcinoma V.1.2018. © National Comprehensive Cancer Network, Inc. 2018. All rights reserved. Accessed May 9, 2018. To view the most recent and complete version of the guideline, go online to NCCN.org. 4. Data on file #1. Basking Ridge, NJ. Ipsen Biopharmaceuticals, Inc.; 2015. 5. Zhang H. Onco Targets Ther. 2016;9:3001-3007. 6. Kalra AV, Kim J, Klinz G, et al. Cancer Res. 2014;74:7003-7013. 7. Data on file #3. Basking Ridge, NJ. Ipsen Biopharmaceuticals, Inc.; 2015.
The information within this site is intended for US healthcare professionals only.
Please choose an option below to continue.